NASDAQ: ETONEton Pharmaceuticals Inc Stock
$14.41+0.13 (+0.91%)
Updated Jan 17, 2025
ETON Price
$14.41
Fair Value Price
N/A
Market Cap
$372.30M
52 Week Low
$3.03
52 Week High
$15.00
P/E
-65.5x
P/B
23.3x
P/S
4.32x
PEG
N/A
Dividend Yield
N/A
Revenue
$35.95M
Earnings
-$5.48M
Gross Margin
60.7%
Operating Margin
-16.74%
Profit Margin
-15.2%
Debt to Equity
1.24
Operating Cash Flow
$2M
Beta
0.84
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ETON Overview
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; EPRONTIA, a liquid formulation of topiramate; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. In addition, the company develops Zonisamide Oral Suspension for the treatment of partial on-set seizures; Lamotrigine for Oral Suspension for the treatment of partial on-set seizures; cysteine injection; dehydrated alcohol injection; and Zeneo hydrocortisone autoinjector. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ETON's potential to beat the market
AStrong Buy
- Stocks with a Zen Rating of Strong Buy (A) had an average return of +32.52% per year. Learn More
Zen Rating Component Grades
C
Value
A
Growth
B
Momentum
A
Sentiment
D
Safety
C
Financials
C
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical
Industry Rating
B
ETON
Ranked#3 of 63
Ranked#3 of 63
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $37.74 | A | |
| $20.82 | A | |
| $8.26 | A |
Be the first to know about important ETON news, forecast changes, insider trades & much more!
ETON News
Overview
Due Diligence Score
–
Industry Average (25)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ETON scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ETON is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ETON is poor value based on its book value relative to its share price (23.3x), compared to the US Drug Manufacturers - Specialty & Generic industry average (2.24x)
P/B vs Industry Valuation
ETON is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more ETON due diligence checks available for Premium users.
Valuation
ETON price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-65.5x
Industry
4.69x
Market
30.45x
ETON price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
23.3x
Industry
2.24x
ETON is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ETON's financial health
Profit margin
Revenue
$10.6M
Net Income
$627.0k
Profit Margin
5.9%
ETON's Earnings (EBIT) of -$6.02M... subscribe to Premium to read more.
Interest Coverage Financials
ETON's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$35.8M
Liabilities
$19.9M
Debt to equity
1.24
ETON's short-term assets ($29.75M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ETON's short-term assets ($29.75M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ETON's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ETON's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$3.0M
Investing
$0.0
Financing
-$385.0k
ETON's operating cash flow ($2.12M)... subscribe to Premium to read more.
Debt Coverage Financials
ETON vs Pharmaceutical Stocks
Eton Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.